The PBM Contract Matters Just as Much as the PBM

PBM proposals are designed to sell.

They often highlight aggressive discounts, strong rebate guarantees, clinical programs, and projected savings. But once the agreement is signed, the contract language controls the relationship.

This is where employers can run into problems.

A contract may allow the PBM to exclude certain claims from guarantees, redefine drug categories, retain manufacturer revenue, limit audit rights, or change parts of the pharmacy network during the contract term.

Many of these provisions are buried deep in the agreement and may never come up during the initial presentation.

That does not mean every PBM is acting improperly. It does mean employers need to understand that the contract often gives the PBM much more flexibility than the proposal suggests.

“Transparent” Does Not Always Mean Fully Transparent

Transparency is one of the most commonly used words in the PBM industry.

Almost every PBM claims to be transparent. The more important question is what that actually means in the contract.

A self-funded employer should be able to clearly understand every way the PBM earns revenue from the plan. That includes administrative fees, rebate retention, pharmacy spread, specialty pharmacy margins, data fees, clinical program fees, and any other form of compensation.

If the PBM is making money from the plan, the employer should know where it is coming from.

That is especially important because PBM compensation can affect which drugs are preferred, which pharmacies are promoted, and how the overall formulary is managed.

True transparency is not a marketing statement. It is clearly defined, measurable, and enforceable contract language.

“100% Pass-Through” Needs a Definition

Employers often hear that a PBM provides 100% pass-through pricing or rebates.

That sounds straightforward, but it may not mean what the employer thinks it means.

Does 100% pass-through include all manufacturer revenue? Are administrative fees excluded? What about specialty drug incentives, data payments, inflation payments, or market-share bonuses?

The answer depends on how the contract defines those terms.

Two PBMs can both claim to pass through 100% of rebates while calculating that amount very differently.

The employer should not have to guess. The contract should clearly identify what is included, what is excluded, when the money will be paid, and how the employer can verify the amount.

PBM contracts are filled with definitions, and those definitions matter.

Terms such as brand drug, generic drug, specialty drug, rebate, average wholesale price, mail order, and limited-distribution drug can all affect financial guarantees.

A drug classified as a brand under one contract may be treated differently under another. A specialty drug may be excluded from a pricing guarantee. Certain claims may not count toward the promised discount.

These details can materially change the final cost to the employer.

This is why PBM contracts cannot be reviewed only at a high level. The definitions section often has just as much financial impact as the pricing section.

A self-funded employer should be able to verify that the PBM is delivering what it promised.

That requires meaningful audit rights.

The employer should be able to review claims pricing, rebate payments, performance guarantees, manufacturer revenue, and other financial terms through an independent auditor.

Some PBM contracts make this difficult. They may limit the number of audits, restrict which auditors can be used, shorten the audit window, or prohibit the review of certain records.

An employer should be cautious anytime a PBM claims to be transparent but places significant restrictions on the employer’s ability to verify the numbers.

Trust is important, but self-funded plan management also requires accountability.

The claims data belongs to the health plan.

At least, it should.

Employers need access to complete, usable pharmacy claims data so they can evaluate utilization, identify cost drivers, compare vendor performance, and make informed decisions.

Some PBM contracts restrict access to data or make it difficult to transfer that data when the relationship ends.

That can make it harder for the employer to evaluate alternatives or move to another PBM.

The contract should clearly state that the employer owns its claims data and can access it in a usable format without unreasonable restrictions.

Employers often spend a great deal of time negotiating pricing and very little time reviewing how the contract can be terminated.

That can be a costly mistake.

A PBM agreement should clearly address contract length, renewal terms, termination rights, outstanding rebates, claims runout, data transfer, and any early termination fees.

Employers should understand how long they are committed, what happens if service deteriorates, and whether they can exit the relationship if the PBM fails to meet performance standards.

A strong contract should create accountability throughout the relationship, not just at renewal.

The best PBM arrangement is not necessarily the one with the largest advertised rebate or the lowest administrative fee.

It is the one where the employer can clearly understand how the PBM makes money, how the plan is being managed, and whether the financial incentives are aligned with the employer’s goals.

For most self-funded employers, the real objective should be lower net pharmacy cost, better clinical outcomes, improved member experience, and fewer surprises.

The contract should support those goals.

Self-funded employers cannot afford to treat the PBM contract as standard vendor paperwork.

Prescription drug costs are too high, specialty medications are too expensive, and the financial arrangements are too complex.

The proposal may get the employer’s attention, but the contract determines the actual outcome.

Before signing a PBM agreement, employers should take the time to understand the definitions, compensation structure, rebate language, audit rights, data ownership, guarantees, and termination provisions.

Because in the PBM world, the most important details are often not in the presentation.

They are in the fine print.